NS
PTGX icon

NBC Securities’s Protagonist Therapeutics PTGX Stock Holding History

NBC Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
2,545
-2
-0.1% -$209 0.02% 694
2026
Q1 		$268K Sell
2,547
-430
-14% -$38.1K 0.02% 741
2025
Q4 		$260K Buy
2,977
+19
+0.6% +$1.55K 0.02% 744
2025
Q3 		$196K Buy
2,958
+393
+15% +$22.3K 0.02% 848
2025
Q2 		$141K Buy
+2,565
New +$123K 0.01% 944

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

NBC Securities's PTGX Position: Q2 2026 in Review

NBC Securities reduced its Protagonist Therapeutics (PTGX) stake by 0.08% in Q2 2026, selling an estimated $209 and leaving 2,545 shares worth $312K. The position accounts for 0.02% of the portfolio, ranked #694.

NBC Securities first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • NBC Securities held 2,545 shares of Protagonist Therapeutics worth $312K as of Q2 2026.
  • NBC Securities sold 2 Protagonist Therapeutics shares in Q2 2026, an estimated $209.
  • Protagonist Therapeutics made up 0.02% of NBC Securities's portfolio in Q2 2026, its #694 holding.
  • NBC Securities first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.